Managing Partner
Dr. Pini Orbach joined Arkin in 2010 and is a Managing Partner overseeing Arkin Bio Ventures and Arkin Bio Capital Funds. Pini has more than 20 years of industry experience as a drug developer and investor and has incubated, invested in and supported numerous biopharmaceuticals companies, including cCAM Biotherapeutics, Redpin Therapeutics, Keros Therapeutics (KROS), Biosight, Cense Pharmaceuticals, UroGen Pharma (URGN) and Human Immunology Biosciences (HiBio).
In his previous roles, Dr. Orbach was the CEO of Israeli-based companies such as Optimata Ltd. and CytoD and worked for U.S.-based companies such as Arisaph Pharmaceuticals and Epix Pharmaceuticals (NASDAQ: EPIX), among others.
Pini holds a Ph.D. in Physiology and Functional Genomics from the University of Florida and completed his postdoctoral fellowship at the Cardiovascular Research Center (CVRC), Harvard Medical School, Massachusetts General Hospital.
Let’s get in touch!
